<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406078</url>
  </required_header>
  <id_info>
    <org_study_id>D5180C00009</org_study_id>
    <nct_id>NCT03406078</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma</brief_title>
  <acronym>SOURCE</acronym>
  <official_title>A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral
      Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the
      Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral
      Corticosteroid Dependent Asthma
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 5, 2018</start_date>
  <completion_date type="Anticipated">December 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Categorized percent reduction from baseline in the daily OCS dose while not losing asthma control.</measure>
    <time_frame>Week 48</time_frame>
    <description>Categorized percent reduction from baseline at Week 48. Percent change from baseline is defined as {final dose-baseline dose}/baseline dose)*100, and the categories of percent change from baseline in daily OCS dose are defined as: ≥90% to ≤100% reduction, ≥75% to &lt;90% reduction, ≥50% to &lt;75% reduction, &gt;0% to &lt;50% reduction, and, no change or any increase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualised asthma exacerbation rate (AAER)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>The annualized exacerbation rate is based on exacerbations reported by the investigator in the eCRF over 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects with 100% reduction from baseline in daily OCS dose at Week 48. Percent change from baseline is defined as {(final dose-baseline dose}/baseline dose)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with daily OCS dose ≤5 mg at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects with daily OCS dose ≤5 mg at Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Proportion of subjects with ≥50% reduction from baseline in daily OCS dose at Week 48. Percent change from baseline is defined as {(final dose-baseline dose}/baseline dose)*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-BD forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in FEV1 at Week 48. FEV1 is defined as the volume of air exhaled from the lungs in the first second of a forced expiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Weekly mean daily Asthma Symptom Score via the daily Asthma Symptom Diary</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in Asthma Symptom Diary score at Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean rescue medication use</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in weekly mean rescue medication use at Week 48. Each timepoint is calculated as weekly means based on daily diary data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean home peak expiratory flow (PEF) (morning and evening)</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in weekly mean morning and evening peak expiratory flow (PEF) at Week 48. Home PEF testing will be performed by the subject in the morning upon awakening and in the evening at bedtime using an electronic, hand-held spirometer. Each timepoint is calculated as weekly means.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weekly mean number of night-time awakening due to asthma</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in weekly mean number of night time awakenings at Week 48. Each timepoint is calculated as weekly mean number of awakenings due to asthma based on daily diary data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Asthma Control Questionnaire 6 (ACQ-6) score</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in ACQ-6 at Week 48. The ACQ-6 captures asthma symptoms and short-acting β2-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Standardized Asthma Quality of Life Questionnaire for 12 years and older (AQLQ(s)+12) total score</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in AQLQ(S)+12 as compared to placebo at Week 48. The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma subjects. The total score is defined as the average of all 32 questions in the AQLQ(S)+12 questionnaire. AQLQ(S)+12 is a 7-point scale questionnaire, ranging from 7 (no impairment) to 1 (severe impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in European Quality of Life - 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L) score</measure>
    <time_frame>Week 48</time_frame>
    <description>EQ-5D at Week 48. The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 response options (no problems, slight problems, moderate problems, severe problems, and extreme problems) that reflect increasing levels of difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of asthma specific resource utilizations</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of asthma specific resource utilizations (e.g. unscheduled physician visits, unscheduled phone calls to physicians, use of other asthma medications) over 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity and Activity Impairment Questionnaire and Classroom Impairment Questionnaire (WPAI+CIQ) score</measure>
    <time_frame>Week 48</time_frame>
    <description>WPAI+CIQ score at Week 48. The WPAI+CIQ consists of questions about how asthma and asthma related issues impact a subject's ability to work, attend classes, and perform regular daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FENO</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in fractional exhaled nitric oxide (FeNO) at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peripheral blood eosinophils</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in blood eosinophil counts at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline from total IgE</measure>
    <time_frame>Baseline, Week 48</time_frame>
    <description>Change from baseline in IgE at week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Serum trough concentrations</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Serum trough concentrations at each scheduled visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Incidence of anti-drug antibodies (ADA)</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Incidence of anti-drug antibodies over 48 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tezepelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezepelumab subcutaneous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tezepelumab</intervention_name>
    <description>Tezepelumab subcutaneous injection</description>
    <arm_group_label>Tezepelumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must have received a physician-prescribed medium- or high-dose ICS as per
             GINA guideline for at least 12 months

          2. Subjects must have received physician prescribed LABA and high dose ICS (total daily
             dose &gt;500μg fluticasone propionate dry powder formulation equivalent) for at least 3
             months. The ICS and LABA can be parts of a combination product, or given by separate
             inhalers.

          3. Additional maintenance asthma controller medications are allowed according to standard
             practice of care i.e., leukotriene receptor antagonists (LTRAs), theophylline,
             long-acting muscarinic antagonists (LAMAs), secondary ICS and cromones. The use of
             these medications must be documented for at least 3 months

          4. Subjects must have received OCS for the treatment of asthma for at least 6 months
             prior to screening and on a stable dose of between ≥ 7.5 to ≤ 30mg (prednisone or
             prednisolone equivalent) daily or daily equivalent for at least 1 month. The OCS dose
             may be administered every other day (or different doses every other day); Average dose
             over two days = The daily dose.

          5. Morning pre-bronchodilator (BD) FEV1 must be &lt; 80% predicted normal

          6. Subjects must have evidence of asthma as documented by post-BD
             (albuterol/salbutatomol) reversibility of FEV1 ≥12% and ≥200 mL (15-30 min after
             administration of 4 puffs of albuterol/salbutamol), documented either in the previous
             12 months

          7. Subjects must have a history of at least 1 asthma exacerbation event within 12 months

          8. Minimum 10 days compliance with the morning and evening eDiary completion and
             OCS,ICS,LABA as well as other asthma controller medications as captured in the eDiary
             during the 14 days prior to randomization

          9. Documented physician-diagnosed asthma for at least 12 months

        Exclusion Criteria:

          1. Any clinically important pulmonary disease other than asthma (e.g. active lung
             infection, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis, pulmonary
             fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung
             cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever
             diagnosed with pulmonary or systemic disease, other than asthma, that are associated
             with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary
             aspergillosis/mycosis, Churg-Strauss syndrome, hypereosinophilic syndrome).

          2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,
             hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic,
             hematological, psychiatric, or major physical impairment that is not stable in the
             opinion of the Investigator and could:

             Affect the safety of the subject throughout the study Influence the findings of the
             study or the interpretation Impede the subject's ability to complete the entire
             duration of study

          3. History of cancer: Subjects who have had basal cell carcinoma, localized squamous cell
             carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate
             in the study provided that curative therapy was completed at least 12 months prior to
             visit 1.Subjects who have had other malignancies are eligible provided that curative
             therapy was completed at least 5 years

          4. A helminth parasitic infection diagnosed within 6 months prior to screening that has
             not been treated with, or has failed to respond to, standard of care therapy.

          5. Current smokers or subjects with smoking history ≥ 10 pack-years and subjects using
             vaping products, including electronic cigarettes. Former smokers with a smoking
             history of &lt;10 pack years and users of vaping or e-cigarette products must have
             stopped for at least 6 months prior to visit 1 to be eligible.

          6. History of chronic alcohol or drug abuse within 12 months

          7. Tuberculosis requiring treatment within the 12 months

          8. History of any known immunodeficiency disorder including a positive human
             immunodeficiency virus (HIV) test.

          9. Major surgery within 8 weeks prior to visit 1 or planned surgical procedures requiring
             general anaesthesia or in-subject status for &gt;1 day during the conduct of the study.

         10. Clinically significant asthma exacerbation, in the opinion of the Investigator,
             including those requiring use of systemic corticosteroids or increase in the
             maintenance dose of OCS within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homestead</city>
        <state>Pennsylvania</state>
        <zip>15120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1414AIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aire</city>
        <zip>C1425BEN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <zip>5500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <zip>B1878FNR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Fernando</city>
        <zip>1646</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAR</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>D-30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz Am Rhein</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03082</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06280</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bursa</city>
        <zip>16059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manisa</city>
        <zip>45030</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipro</city>
        <zip>49007</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kherson</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <zip>43000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 14, 2018</study_first_submitted>
  <study_first_submitted_qc>January 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

